Michael K Lee

Title: Michael K Lee: Innovator in Alzheimer's Drug Screening

Introduction

Michael K Lee is a prominent inventor based in Baltimore, MD (US). He has made significant contributions to the field of drug screening for Alzheimer's disease. His innovative approach focuses on utilizing mutant mouse hippocampal cells to identify potential treatments for this debilitating condition.

Latest Patents

Michael K Lee holds a patent for "Diagnostic methods for drug screening for Alzheimer's disease." This patent outlines methods for screening candidate drugs aimed at treating Alzheimer's disease. By employing tissue slices of mutant mouse hippocampal cells, which possess an extra copy of a mutant form of the presenilin-1 gene, he discovered that these cells exhibit enhanced potentiation to tetanic stimuli. The method involves subjecting both wild-type and mutant hippocampal cells to tetanic stimuli in the presence of a candidate drug. A successful candidate is indicated by a reduction in the enhanced potentiation of the mutant cells without significant changes in the wild-type cells. This innovative approach has the potential to streamline the drug discovery process for Alzheimer's treatments.

Career Highlights

Michael K Lee is affiliated with Cold Spring Harbor Laboratory, where he continues to advance research in neurodegenerative diseases. His work has garnered attention for its potential impact on the future of Alzheimer's treatment.

Collaborations

Michael collaborates with esteemed colleagues, including Roberto Malinow and Shahid Zaman, who contribute to the research efforts at Cold Spring Harbor Laboratory.

Conclusion

Michael K Lee's innovative work in drug screening for Alzheimer's disease represents a significant advancement in the search for effective treatments. His contributions to the field are invaluable and highlight the importance of continued research in neurodegenerative diseases.